JUN and pancreatic ductal adenocarcinoma: Zhou et al. (32) conducted a study in which they found that the addition of irbesartan to chemotherapy demonstrated potential for enhancing therapeutic effectiveness in patients with pancreatic ductal adenocarcinoma (PDAC) who exhibited elevated c-Jun expression levels.